<DOC>
	<DOCNO>NCT02314312</DOCNO>
	<brief_summary>Single center , open-label randomized-control trial Population : de novo 48 kidney transplant recipient ( age 18-75 year ) ECD/AKI donor Compare : everolimus low dose CNI prednisolone versus standard immunosuppressive regimen Objective : To evaluate efficacy everolimus low dose CNI de novo kidney transplant recipient ECD/AKI donor Primary endpoint : Mean eGFR ( CKD-EPI ) 12 month post-transplantation</brief_summary>
	<brief_title>Efficacy Safety Everolimus de Novo Kidney Transplant Recipients ECD AKI Donors</brief_title>
	<detailed_description>Secondary Endpoints : - To assess renal function mean eGFR ( Cockcrault Gault formula ) , -Month 6 12 post-transplantation - To assess incidence individual composite endpoint include BPAR , graft loss death Month 6 12 post-transplantation - To assess incidence duration renal replacement therapy - To assess incidence chronic allograft nephropathy ( IF/TA ) Month 12 - To assess renal function mean serum creatinine Month 6 12 post-transplantation - To compare overall safety tolerability ( incidence AEs SAEs , infection , discontinuation due AEs , lab abnormality , wind surgical complication ) Month 6 12 post-transplantation Definition ECD - Brain-dead donor &gt; 60 year old - Donor age &gt; 50 year old two follow criterion ; - History HT - Terminal SCr . ≥ 1.5 mg/dL - Death cerebrovascular accident Definition AKI donor - Brain-dead donor increase SCr . ≥ 0.3 mg/dL baseline</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Age 1875 year Recipients first DDKT ECD AKI donor Patient willing participate study Multiorgan recipients Organ donation Cardiac Death ( DCD ) . PRA &gt; 20 % historical peak PRA &gt; 50 % Patients lose first graft due immunological reason within first year posttransplantation . ABO incompatible transplant positive crossmatch Patients chronic inflammatory bowel disease . Severe allergy require acute treatment , know hypersensitivity everolimus , thymoglobulin Thrombocytopenia ( platelet &lt; 75,000/mm3 ) , ANC &lt; 1,500 /mm3 leucopenia ( leucocytes &lt; 2,500/mm3 ) , Hb &lt; 6 g/dL Chronic active HCV , HIV , HBsAg positive History malignancy last five year , except squamous basal cell carcinoma skin . Ongoing infection require treatment systemic antibiotic . Patient severe hypercholesterolemia ( &gt; 300 mg/dL ) hypertriglyceridemia ( &gt; 600 mg/dL ) control Evidence severe liver disease . Severe restrictive obstructive pulmonary disorder . Pregnant nursing ( lactate ) woman . Patient refuse participate study would like withdraw study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Kidney transplantation</keyword>
	<keyword>ECD</keyword>
</DOC>